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Abstract: A label-free immunosensor platform based on excessively tilted fiber gratings (Ex-
TFGs) was developed for highly specific and fast detection of human N-terminal pro-B-type 
natriuretic peptide (NT-proBNP), which is considered a powerful biomarker for prognosis 
and risk stratification of heart failure (HF). High-purity anti-NT-proBNP monoclonal 
antibodies (MAbs) prepared in our laboratory were immobilized on fiber surface through the 
staphylococcal protein A (SPA) method for subsequent specific binding of the targeted NT-
proBNP. Utilizing fiber optic grating demodulation system (FOGDS), immunoassays were 
carried out in vitro by monitoring the resonance wavelength shift of Ex-TFG biosensor with 
immobilized anti-NT-proBNP MAbs. Lowest detectable concentration of ~0.5ng/mL for NT-
proBNP was obtained, and average sensitivity for NT-proBNP at a concentration range of 
0~1.0 ng/mL was approximately 45.967 pm/(ng/mL). Several human serum samples were 
assessed by the proposed Ex-TFG biomarker sensor, with high specificity for NT-proBNP, 
indicating potential application in early diagnosing patients with acute HF symptoms. 
© 2016 Optical Society of America 
OCIS codes: (280.1415) Biological sensing and sensors; (060.2370) Fiber optics sensors; (170.0170) Medical optics 
and biotechnology. 
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1. Introduction 
Immunoassays of protein biomarkers constitute a very powerful tool in the early diagnosis, 
prognosis, and treatment of serious pathologies such as neurological disorders, cardiovascular 
diseases and cancer [1–3]. So far, label-free immunosensors based on electrochemical or 
piezoelectric principles have been widely reported in immunoassays related to pathologies or 
biomedical research fields [4–6]. Besides, owning to high sensitivity and specificity, compact 
structure, and capacity of rapid detection, label-free optical immunosensors attract increasing 
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attention from researchers in recent years. Indeed, many types have been proposed, including 
optical biosensors based on interferometric strategy [7, 8], surface Plasmon resonance (SPR) 
based biosensors [9, 10], a planar waveguide ring resonator designed for detecting multiple 
lung cancer biomarkers [11], and long period fiber grating (LPFG) for differentiated thyroid 
cancer biomarker detection [12]. 
In this work, we propose an easily-made and label-free immuno-sensing platform based 
on excessively tilted fiber gratings (Ex-TFGs) [13] for the specific and fast detection of 
human heart failure (HF) biomarkers. Human N-terminal pro-B-type natriuretic peptide (NT-
proBNP), a non-bioactive fragment containing 76 terminal amino acids, is a very good 
cardiac biomarker reflecting ventricular volume expansion, pressure overload, and 
myocardial damage presence and even its degree [14]. Therefore, detecting serum NT-
proBNP levels has been approved as an extremely effective method and is widely used in the 
early diagnosis, prognosis or risk stratification of HF in clinical applications [15]. Indeed, 
NT-proBNP levels in patients with HF related diseases are overtly increased compared with 
those of healthy individuals. In general, diagnosis in patients with acute HF symptoms is 
achieved with fixed cutoff values for NT-proBNP of 0.45 ng/mL and 0.9 ng/mL for ages of 
<50 and 50~75, respectively [16]. Currently, many methods have been applied for NT-
proBNP detection, with each having several disadvantages. For example, radioimmunoassay 
(RIA) [17] and immunoradiometric assay (IMRA) [18] are complex, time consuming and 
expensive, and may also cause radioactive contamination. Other methods, such as enzyme 
linked immunosorbent assay (ELISA) [19], electrochemiluminescence [20], and time-
resolved immunofluorescence [21], are commonly used for NT-proBNP quantification, but 
require large equipment and are less convenient or fast, which makes them unsuitable for 
emergency and on-site inspections. 
The Ex-TFG immuno-sensing platform designed in this study focused on potentially 
excluding/including acute HF patients through evaluation of NT-proBNP concentrations in 
human serum in early clinical diagnosis. Ex-TFG based immunosensor development 
comprised several surface-modified steps, including silanization, adsorption of staphylococcal 
protein A (SPA), and immobilization of anti-NT-proBNP monoclonal antibodies (MAbs). 
The most critical step was the immobilization of high-purity anti-NT-proBNP MAbs through 
the SPA biofilm. Immunoassays, monitoring the specific binding between anti-NT-proBNP 
MAbs and NT-proBNP, were carried out in vitro by monitoring the core-to-cladding mode 
coupling wavelength shift of Ex-TFG immunosensors. 
2. Material and fabrication 
2.1 Fabrication of Ex-TFGs and apparatus 
Ex-TFGs used as the sensing platform were structured with wide tilted angle (>80°) refractive 
index fringes inscribed in the core region of SM28 fibers to couple a light portion from the 
core mode to high-order cladding modes [13]. Using the scanning mask technique and 
doubled frequency Ar+ laser emitting at 244 nm with a power level of ~150 mW, a 
customized amplitude mask (period of 6.6μm) was tilted at 78°. This produced approximately 
81° excessively titled fringes with a period along the fiber axis of ~32µm in the core region 
(See inset of Fig. 1(a)). Such structure can couple the phase-matching light from the core 
mode to co-propagating high-order cladding modes. The phase matched conditions can be 
expressed as 
 ,( ) / cos .
eff eff
co cl co cl m Gn nλ θ− = − ⋅ Λ  (1) 
where co clλ − is the resonance wavelength, effcon and ,effcl mn are the effective mode indexes of the 
fundamental core and mth cladding modes, respectively, GΛ  is the normal period of grating, 
and θ  is the tilt angle of the fringes. Usually, tilt angles of the fabricated Ex-TFGs were from 
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79° to 83°. The surrounding refractive index (RI) sensitivity of the sensor is affected by a tilt 
angle increase, but the influence is low in this range [22]. In order to guarantee the cladding-
mode resonance to appear in the ~1550 nm wavelength range, 81° tilt angle was selected. 
Such Ex-TFGs could be regarded as LPFGs with a much smaller grating period, thus are 
inherently very sensitive to RI and can be implemented as an optical fiber biosensor platform 
[13]. RI and temperature properties for Ex-TFGs have been described in previous reports by 
our group [23]. Due to the highly standardized fabrication process, Ex-TFGs are inexpensive, 
easily-made and reproducible, unlike interferometer-based or ring-resonator-based biomarker 
sensors. Therefore, we fabricated several Ex-TFGs with identical parameters for the 
following experiments. 
The experimental apparatus to assess the transmission spectrum is shown in Fig. 1(a). The 
fiber optic grating demodulation system (FOGDS) (MOI-SM125, accuracy of 1pm) is 
integrated with a sweep laser light source (1510~1590 nm, 1Hz). Light from one channel (i.e. 
output channel) of the FOGDS was launched into the SM28 fiber, while the reflected light 
was isolated by a fiber optic isolator (FOI). A polarizer was used to produce linearly polarized 
light, whose polarization direction was adjusted by a three ring polarization controller (PC). 
Transmission spectrum of Ex-TFGs was recorded by another channel (i.e. input channel) of 
the FOGDS. 
 
Fig. 1. (a) Experimental setup, Inset: micrograph of the Ex-TFG’s core region. (b) 
Transmission spectrum of a fabricated Ex-TFG with the fast-axis polarized mode at 
1550~1558 nm region fully excited, and (c) corresponding RI and temperature properties. 
Figure 1(b) shows the transmission spectrum located at the 1550~1558 nm region for one 
of the fabricated Ex-TFGs with fast-axis polarized mode fully excited, showing that the 
FWHM (~2.3 nm) is much narrower than that of the conventional LPFG-based or SPR-based 
strategy (usually >~20 nm and >~50 nm, respectively). Theoretically speaking, measurement 
accuracy of Ex-TFGs would be much better than that of conventional LPFGs. Furthermore, 
calibrated results showed that RI and temperature sensitivities of the fabricated Ex-TFGs 
were 150.0~160.0 nm/RIU and 4.9~5.2 pm/°C, respectively, for each fast-axis polarized 
mode at the 1550~1558 nm region. Figure 1(c) depicts the sensing properties for the Ex-TFG 
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resonance spectrum shown in Fig. 1(b), indicating a much higher RI sensitivity but far lower 
temperature cross-talk effect than values obtained for conventional LPFGs [24]. 
In a word, although some interferometer-based [7, 8] or ring-resonator-based [11] 
biosensors exhibit very high RI sensitivity and extremely good Q-factor, their fabrication 
processes are relatively more complicated, with rigid technical requirements, compared with 
the proposed Ex-TFG sensors. Meanwhile, SPR-based [9, 10] and conventional LPFG-based 
[12] biosensors have too wide FWHM, which results in relatively low detection accuracy. 
Therefore, all the above advantages make Ex-TFGs a favorable platform for biochemical 
sensing. 
2.2 Reagents 
3-Aminopropyltriethoxysilane (APTES), highly purified SPA, fluorescein isothiocyanate 
(FITC), bovine serum albumin (BSA), 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide 
hydrochloride (EDC), N-Hydroxysuccinimide (NHS), polyethylene glycol (PEG-1500), 
hypoxanthine-aminopterin-thymidine (HAT) and hypoxanthine-thymidine (HT) 
supplemented medium were purchased from Sigma-Aldrich, China. Glycine and isopropyl-β-
D-thiogalactoside (IPTG) were from Gen-View Scientific, USA. Phosphate buffered solution 
(PBS) (0.01M, pH7.4) and 4-morpholineethanesulfonic acid hydrate (MES) (0.1M, 
pH5.5~6.7) buffered solution were obtained from Wuhan Boster Biological Technology, 
China. Protein A and G chromatography media were from GE, USA. NdeI and Xhol were 
purchased from TAKARA, Japan. The pET20b empty vector was kindly provided by the 
Third Military Medical University, China. Standard sample of NT-proBNP (initial 
concentration of 1.57 mg/mL) was purchased from Chongqing Tansheng Technology (China) 
and diluted in PBS (0.01M, pH7.4) to different concentration levels of 0.1, 0.5, 1.0, 10, 50, 
100, 500 and 1000 ng/mL, for immunoassays. 
2.3 Preparation and identification of anti-NT-proBNP MAbs 
To prepare highly specific NT-proBNP antibodies, the 24 amino acids at the amino terminus 
of NT-proBNP were used as target antigen; four target antigen repeats were connected by a 
flexible amino acid fragment (GGGGS), generating a new peptide with a total of 121 amino 
acids (target antigen - GGGGS - target antigen - GGGGSGGGGSGGGGS - target antigen - 
GGGGS - target antigen), termed NT-proBNP T3P × 4. The NT-proBNP T3P × 4 gene was 
amplified by PCR and cloned into pET20b. After identification by digestion and sequencing, 
it was named T3P × 4-pET20b (Fig. 2(a) and 2(b)). Then, the T3P × 4-pET20b plasmid was 
transformed into E. coli BL21. The recombinant protein was induced by 0.5 mM IPTG at 
28°C for 8 hours, denatured and purified by Ni affinity chromatography, and analyzed by 
SDS-PAGE. BALB/c mice were immunized four times with the purified NT-proBNP, and 
spleen cells and SP2/0 cells were fused with PEG-1500 to prepare murine anti-NT-proBNP 
MAbs. SDS-PAGE (10%) revealed a 12 KD recombinant protein purified from E. coli cell 
lysate (Fig. 2(c)). These results indicated that NT-proBNP was highly expressed in E. coli 
BL21. A hybridoma cell line secreting MAbs, named 5E7, was developed by two subclones. 
After purification by Protein G affinity chromatography, 12 mg NT-proBNP MAbs with 
95.70% purity at a concentration of 1.237 mg/mL were obtained (Fig. 2(d)). The specificity of 
MAbs was identified by Western-blot (Fig. 2(e)). 
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 Fig. 2. Preparation and purification of NT-proBNP MAbs. (a) Amplification of the NT-
proBNP gene by PCR. Lane 1: PCR product from the NT-proBNP gene. (b) Identification of 
recombinant vector by restriction endonuclease analysis. Lane 1: T3P × 4-pET20b before 
digestion; Lane 2: T3P × 4-pET20b digested by NdeI and Xhol. (c) Identification of NT-
proBNP by SDS-PAGE. Lane 1: NT-proBNP expressed in E. coli transformed with the T3P × 
4-pET20b vector induced by IPTG; Lane 2: NT-proBNP purified by Ni affinity 
chromatography. (d) SDS-PAGE analysis of purified NT-proBNP MAbs from the ascetic 
fluid. Lane 1: Purified NT-proBNP MAbs. Heavy and light chains are shown. (e) Identification 
of NT-proBNP MAbs by Western-blot. Lane 1-2: NT-proBNP purified by Protein G affinity 
chromatography. 
2.4 Surface modification of Ex-TFGs 
Fabricated Ex-TFGs of identical parameters were initially soaked in the HNO3 solution (5% 
v/v) for ~2h at ~40°C, and thoroughly washed with de-ionized water and ethanol. The cleaned 
Ex-TFGs were immersed in H2SO4 (95% v/v in H2O2) for ~1h at room temperature to activate 
the hydroxyl groups on the fiber surface. Then residual liquid droplets were removed using a 
pipette, before drying in a convection oven for ~6h at ~60°C. Afterwards, the –OH activated 
Ex-TFGs were immersed in APTES (10%v/v in absolute ethanol) for ~30 min at room 
temperature, where APTES molecules would bind –OH groups on the fiber surface by 
silicon-oxygen bonds, as shown in Fig. 3(a). Then, the silanized Ex-TFGs were washed with 
absolute ethanol and de-ionized water to thoroughly remove non-bound silanized compounds, 
and dried in convection oven for ~20 min at ~37°C. 
 
Fig. 3. Chemical bonds of (a) APTES, (b) SPA, and (c) anti-NT-proBNP MAbs on the fiber 
surface. 
SPA, a type I membrane protein extracted from staphylococcus aureus, has been shown to 
bind the immunoglobulin G (IgG) Fc fragment in serum from many mammals without 
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affecting the bioactivity of the IgG Fab fragment (i. e. the antigen-binding site) while 
maintaining highly outward-oriented features [25, 26]. Therefore, it has been used as antibody 
linker for several decades. First, EDC/NHS (0.9 mg/1.2 mg) was added into an SPA solution 
(0.3 mg/mL in MES buffered solution, pH 6.0, 1 mL) for ~25 min to activate the carboxyl 
group of SPA. Afterwards, the silanized Ex-TFGs were incubated in the activated SPA 
solution (300µL, pH 7.2) for ~30 min at room temperature to establish covalent bonds 
between SPA and APTES (Fig. 3(b)). Then, these sensors were washed with PBS to remove 
unbound SPA molecules, and air dried. The above process is simple and it need only one time 
process to active the carboxyl group of SPA for the following immobilization of anti-NT-
proBNP MAbs. 
Finally, the SPA-modified Ex-TFGs were separated into two groups, labeled ‘S1’ and 
‘S2’, respectively. Immobilization of anti-NT-proBNP MAbs to the fiber surface was 
performed by incubating ‘S1’and ‘S2’ Ex-TFGs with the high-purity anti-NT-proBNP MAbs 
solution (in PBS, phase volume 180µL) at a concentration of 0.30 mg/mL and 0.15 mg/mL, 
respectively, for ~40 min at room temperature. Then, the functionalized Ex-TFGs were 
washed several times with PBS to remove unbound anti-NT-proBNP MAbs. Chemical bonds 
with anti-NT-proBNP MAbs on the fiber surface are described in Fig. 3(c). 
3. Results and discussion 
3.1 Surface modification monitored by resonance spectra of Ex-TFGs 
Using the experimental setup in Fig. 1(a), spectra of the Ex-TFGs immersed in blank PBS 
(0.01M, pH7.4) were recorded after each step of surface modification. Figure 4(a) represents 
the spectrum evolution for one of the Ex-TFGs; Fig. 4(b) is the corresponding wavelength 
shift, indicating that due to the adsorption of APTES, SPA, and anti-NT-proBNP MAb layers, 
resonance wavelength shifted by ~0.465 nm, ~0.705 nm and ~1.01 nm, respectively, 
compared with that (~1553.300 nm) of the bare Ex-TFG. Other fabricated Ex-TFGs 
underwent similar spectrum evolution. This outcome was expected because an increase of 
outer layer thickness leads to an increase in the surrounding RI. Therefore, as additional 
layers are immobilized on the fiber surface, resonance wavelengths of Ex-TFGs would red-
shift due to the RI sensitivity of the sensor showing a positive value. However, because 
APTES, SPA and anti-NT-proBNP MAb layers are so thin that the change in the surrounding 
RI is very small, only a small wavelength shift was obtained. 
 
Fig. 4. (a) Spectrum evolution for an Ex-TFG and (b) the corresponding wavelength shift in 
every step of the surface modification. 
3.2 Surface characteristics of modified Ex-TFGs 
Uniformity of the APTES and SPA layer on the fiber surface was assessed by scanning 
electron microscopy (SEM, JSM-6460LV). Surface morphology of the bare, silanized, and 
SPA-modified fibers are shown in Fig. 5(a), 5(b) and 5(c), respectively. The surface of the 
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bare fiber was glossy, but became plicate after modification by APTES and SPA. 
Consequently, the methodology used for silanization and the subsequent SPA modification 
produced nicely adherent layers on the fiber surface. 
However, as shown in Fig. 5(b) and 5(c), there were no overt differences between 
silanized and SPA-modified fibers; thus, to provide a visual evidence for the SPA layer 
adhering on the fiber surface, several bare fibers were submitted to the same modification 
process described in Section 2.4. For one of them, a prepared FITC-labeled SPA solution also 
activated by EDC and NHS chemistry was used, to modify its surface after APTES treatment. 
After many washes with PBS, the FITC-labeled-SPA modified fiber was inspected by 
inverted fluorescence microscopy (Olympus Venox). As shown in Fig. 5(d), strong glowing 
fluorescence appeared, providing fairly good evidence of a consistent SPA layer established 
on the fiber surface. However, no fluorescence was observed for APTES-treated fibers 
(without FITC-labeled-SPA treatment). Therefore, this fluorescence can be attributed to the 
presence of SPA molecules bound on the fiber surface. 
 
Fig. 5. Micrographs for surface morphology of (a) bare, (b) silanized, and (c) SPA-modified 
fibers, observed by SEM. (d) Fluorescent micrograph of the FITC-labeled-SPA modified fiber 
obtained by inverted fluorescence microscopy. 
3.3 NT-proBNP detection using Ex-TFG based immunosensors 
As shown in Fig. 1(a), the ends of the Ex-TFG immunosensor are fixed on two separated 
glass slides with a movable slide between them; meanwhile, the body of the sensor is on the 
middle slide’s surface. First, a reference spectrum was recorded after introducing a blank PBS 
(0.01M, pH7.4) to cover the whole sensor. Subsequently, the prepared NT-proBNP sample 
solutions with different concentration levels (phase volume of 200µL) were analyzed by the 
immunosensor in turn, with the sensing region sealed with a small vessel to prevent sample 
evaporation during the immunoassay. For each concentration, it would take 2~3 min for the 
sensor to obtain a stable resonance wavelength, which signified a complete specific binding 
reaction between the anti-NT-proBNP MAbs and NT-proBNP antigens near the fiber surface. 
Then, the sensor was washed several times with blank PBS before assaying the next 
concentration level. 
Resonance spectra of the Ex-FBGs would red-shift with increased NT-proBNP 
concentration. Figure 6(a) represents the spectrum evolution for one of the immunosensors, 
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with overt redshift. This is reasonable because the RI sensitivities of Ex-TFGs are positive, 
and effective RI values for cladding modes are affected by the specific binding between NT-
proBNP antigens and anti-NT-proBNP MAbs. 
For the first group of Ex-TFGs (‘S1’), average wavelength shifts for all concentration 
levels are shown in Fig. 6(b) (Blue circle). The above immunoassays were also carried out 
under the same conditions in the second group of Ex-TFGs (‘S2’), whose average 
wavelengths varied with the NT-proBNP level as shown in Fig. 6(b) (Red Cross). The two 
groups of immunosensors did not overtly respond until NT-proBNP concentration was ≥0.5 
ng/mL; thus, the lowest detectable concentration was estimated at ~0.5 ng/mL. Moreover, the 
inset in Fig. 6(b) showed that the average wavelength shifts for ‘S1’ were between ~25 and 
~45pm at NT-proBNP concentrations of 0.5 and 1.0 ng/mL, respectively, and were nearly 
identical to those (i.e. ~20 pm and ~45 pm, respectively) of the second group (‘S2’). Average 
sensitivity for NT-proBNP detection at concentrations ranging from 0 to 1.0 ng/mL was 
~45.967 pm/(ng/mL) with an R2 of ~0.997 by linear fitting [inset of Fig. 6(b)]. Although the 
immunosensor established in this study is not as sensitive as ELISA [19], it can be operated 
more easily and quickly, with more consistent results, and no expensive reagents or 
equipment required. 
 
Fig. 6. (a) Spectrum evolution for one of the Ex-TFG immunosensors as NT-proBNP levels 
change from 0~1000 ng/mL. (b) Average wavelength shifts for the first (‘S1’) and second 
(‘S2’) groups of Ex-TFGs. Relative standard deviation (RSD) from several independent 
measurements: 0.032 < RSD < 0.222 for ‘S1’ and 0.045 < RSD < 0.250 for ‘S2’; Inset: 
Magnified picture at the concentration range of 0~1.0 ng/mL. 
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The inset of Fig. 6(b) shows that the linear dynamic range of the sensor was small, only 
0~1.0 ng/ml. This is due to an active length of the sensor of only ~15 mm; thus, the amounts 
of anti-NT-proBNP MAbs immobilized on the fiber surface are not more than enough, 
leading to the quantity of NT-proBNP molecules absorbed by the anti-NT-proBNP MAbs 
being relatively low. Therefore, theoretically speaking, the linear dynamic range of the sensor 
could be increased by fabricating a longer Ex-TFG immunosensor. 
Besides, according to Fig. 6(b), the redshift of the resonance wavelength became saturated 
gradually; this was due to available Fab antigen binding fragments of anti-NT-proBNP MAbs 
gradually being decreased with increasing test number. However, the average saturation point 
(~500 ng/mL) of the first group of Ex-TFGs (‘S1’) was far higher than that (~100 ng/mL) of 
the second group (‘S2’), which might be attributed to the concentration (0.30 mg/mL) of anti-
NT-proBNP MAbs used in the immobilization step for ‘S1’ being two times that of the 
second group (0.15 mg/mL), thus leading to a large difference in available anti-NT-proBNP 
MAbs immobilized on the fiber surface. This corroborates the findings of average wavelength 
shift (~285 pm) of the first group being ~2.4 times greater than that (~120pm) of the second 
group at saturation points, i.e. ~500 ng/mL and ~100 ng/mL, respectively. 
3.4 NT-proBNP detection in human serum samples 
With the concept that sectional fixed values for NT-proBNP levels are 0.45 ng/mL (for <50 
years old patients) or 0.9 ng/mL (for 50~75 years old patients) in excluding patients with 
acute HF symptoms [16], the potential application in the clinic of the current sensing platform 
was investigated. As shown in the inset of Fig. 6(b), the wavelength shift of calibrated Ex-
TFG immunosensors for NT-proBNP levels in serum from acute HF patients was estimated at 
>20 pm (<50 years old patients) or >45 pm (50~75 years old patients). 
Human serum samples with known NT-proBNP levels (2 acute HF patients and 2 healthy 
volunteers) were obtained from the First Affiliated Hospital of Chongqing Medical University 
(CQMU), Chongqing, China, and kept at −80°C until analysis. The study protocol was 
approved by the ethics committee of the First Affiliated Hospital of CQMU, and informed 
consent was obtained from each subject. An unused Ex-TFG immunosensor of the first group 
(‘S1’) was initially immersed in a blank PBS and the observed resonance wavelength was 
recorded as the reference. Each serum sample was analyzed for ~3 min by this calibrated Ex-
TFG immunosensor in turn. After each immunoassay, the sensor was washed with blank PBS 
several times; resonance spectra were recorded under identical conditions. Wavelength shifts 
obtained with this immunosensor for serum samples are listed in Table 1, indicating good 
consistency with early diagnosis results of the hospital. Therefore, the immunosensor worked 
effectively in excluding or including acute HF. Since that analyses were carried out with 
clinical serum samples, and given that other types of non-specific antigens exist in this 
complex environment, the above results revealed a high specificity of the proposed 
immunosensors for NT-proBNP. 
Table 1. NT-proBNP Level in Serum Samples Analyzed by an Ex-TFG Immunosensor 
(‘S1’) 
Sample Age NT-proBNP Level (ng/mL) Diagnosis by hospital 
Wavelength shift 
(pm) Result 
1 40 0.08 health  ± 5.0 Exclude 
2 64 0.13 health 5.0 ± 5.0 Exclude 
3 48 0.76 acute left HF 30.0 ± 5.0 Not exclude 
4 73 1.57 acute left HF 65.0 ± 10.0 Not exclude 
Furthermore, NT-proBNP detection in serum samples was also performed with an unused 
Ex-TFG immunosensor of the second group (‘S2’), but consistency with previously calibrated 
data (inset of Fig. 6(b), Red Cross) was not good, that is, wavelength shifts at similar NT-
proBNP levels were overtly larger than those evaluated by the calibration data. This might be 
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due to many free SPA molecules still not binding anti-NT-proBNP MAbs as a consequence of 
the low concentration (0.15 mg/mL) of anti-NT-proBNP MAbs used in the immobilization 
step. Such MAb level might have been insufficient, leading to free SPA molecules that could 
easily bind other types of antibodies in the sophisticated environment of a real serum sample. 
On the other hand, these findings suggested that anti-NT-proBNP MAbs used at ~0.3 mg/mL 
in the immobilization step as in ‘S1’, could bind all SPA molecules absorbed on the fiber 
surface. 
It should be noted that the above experiments were designed for analyzing NT-proBNP 
under certain test conditions (active length of Ex-TFGs = 15 mm; SPA solution = 0.3 mg/mL; 
anti-NT-proBNP MAb solution = 0.3 mg/mL; phase volume of the NT-proBNP solution = 
200µL). However, these parameters are selectable according to specific requirements. In such 
a case, system calibration should be performed anew. 
4. Conclusions 
We presented an easily-made and label-free immunosensor based on Ex-TFG for the highly 
specific and fast detection of the human HF biomarker NT-proBNP. Lowest detectable 
concentration of ~0.5 ng/mL for NT-proBNP was obtained, with average sensitivity for NT-
proBNP detection in the concentration range of 0~1.0 ng/mL of ~45.967 pm/(ng/mL). Human 
NT-proBNP levels in serum from a few clinical samples were detected, demonstrating that 
the Ex-TFG biomarker sensor for excluding/including acute HF is feasible and could be used 
in the early clinical diagnosis. The basic concept of the developed device can be easily 
expanded to obtain label-free biosensors for a wide range of protein biomarkers. Considering 
that a more precise and sensitive detection of NT-proBNP in human serum is required for 
diagnosis, prognosis or risk stratification of HF in clinical applications [15], further research 
will focus on improving the minimum detection limit and sensitivity of the proposed label-
free biomarker sensor; this could be realized by using Ex-TFGs inscribed in thin-core-
cladding fibers (SM1500) as bio-sensing platforms [27]. 
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